10 Biggest Losers of This Week

5. Geron Corp. (GERN)

Geron Corp. (GERN) saw its shares drop by 4.3 percent to $3.34 from $3.49 apiece. Geron (GERN) is a biopharmaceutical company. Geron recently announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its drug Rytelo for treating specific types of myelodysplastic syndromes. The European Commission will now review this recommendation, with a final decision on market authorization expected in the coming months.

According to analysts, the company continues to ingest news of the company’s earnings performance, with the firm still booking a net loss in the third quarter of the year—$26.4 million, albeit lower than the $44.8 million reported in the same period last year.

However, the first nine months of the year saw a higher net loss of $149.2 million as compared with the $132.2 million registered year-on-year.